Key Takeaways
- • Vivo Capital, a Palo Alto-based healthcare investment firm with approximately $7bn in capital under management, appointed Neetesh Kumar as Managing Partner to co-lead its buyout and private equity strategy in the U.S., according to a Business Wire release dated September 10, 2026.
- • Kumar brings more than 30 years of experience across private equity, growth equity, venture capital and credit, and will help establish Vivo's presence in New York.
- • Kumar joins from Spruceview Capital Partners, where he was a Partner and most recently Adviser, leading private markets investments with responsibility for more than $4 billion in assets.
- • The appointment reflects Vivo's effort to grow its growth and buyout business, with Kumar's expertise at the intersection of investment, technology and artificial intelligence positioned to address opportunities as AI transforms healthcare.
Summary
Vivo Capital, a leading global healthcare investment firm founded in 1996, has appointed Neetesh Kumar as Managing Partner, according to a Business Wire announcement. Kumar will co-lead Vivo's buyout and private equity investment strategy with a focus on the U.S. market and will help establish the firm's presence in New York. The firm describes the move as strengthening its senior investment leadership as it builds on three decades of investing in healthcare and the life sciences.
Kumar brings more than 30 years of experience across private equity, growth equity, venture capital and credit. He joins Vivo from Spruceview Capital Partners, where he served as a Partner and, most recently, Adviser, leading private markets investments with responsibility for more than $4 billion in assets. His earlier roles include senior investment positions at J.P. Morgan Chase Retirement Plan, Rho Fund Investors, the University of California Investments, and the growth buyout firms One Equity and Banc One Capital Partners. He began his career in technology, including as a founding team member of Vetri Systems and as a Manager at Andersen Consulting, now Accenture. Kumar holds an MBA from the University of Chicago and an MS in Computer Science from Wayne State University, and has completed coursework at MIT in Artificial Intelligence in Pharma and Biotech and Cell Therapy Biomanufacturing.
Dr. Frank Kung, Co-Founder and Managing Partner of Vivo Capital, said the firm has known Kumar for close to 20 years and that his private markets experience will help grow the buyout and growth strategy. Kumar said the convergence of healthcare and technology is creating new opportunities, along with greater demand for optimized cost structures in pharma supply chains and pharma services. The firm states that Kumar's perspective will help it pursue emerging opportunities as AI and other technologies transform healthcare. Vivo currently has approximately $7bn of capital actively managed across its venture capital, growth equity, buyout and public equities strategies, has invested in more than 460 public and private companies globally, and has a team of more than 70 professionals with offices in Palo Alto and Asia.
Kumar brings more than 30 years of experience across private equity, growth equity, venture capital and credit. He joins Vivo from Spruceview Capital Partners, where he served as a Partner and, most recently, Adviser, leading private markets investments with responsibility for more than $4 billion in assets. His earlier roles include senior investment positions at J.P. Morgan Chase Retirement Plan, Rho Fund Investors, the University of California Investments, and the growth buyout firms One Equity and Banc One Capital Partners. He began his career in technology, including as a founding team member of Vetri Systems and as a Manager at Andersen Consulting, now Accenture. Kumar holds an MBA from the University of Chicago and an MS in Computer Science from Wayne State University, and has completed coursework at MIT in Artificial Intelligence in Pharma and Biotech and Cell Therapy Biomanufacturing.
Dr. Frank Kung, Co-Founder and Managing Partner of Vivo Capital, said the firm has known Kumar for close to 20 years and that his private markets experience will help grow the buyout and growth strategy. Kumar said the convergence of healthcare and technology is creating new opportunities, along with greater demand for optimized cost structures in pharma supply chains and pharma services. The firm states that Kumar's perspective will help it pursue emerging opportunities as AI and other technologies transform healthcare. Vivo currently has approximately $7bn of capital actively managed across its venture capital, growth equity, buyout and public equities strategies, has invested in more than 460 public and private companies globally, and has a team of more than 70 professionals with offices in Palo Alto and Asia.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.